RB1 and neoplasm: Recently, several oncolytic viral drugs have been approved for clinical trials through i.t. treatment.[3] One of the most common approaches to construct a tumor‐selective virus is a 24‐bp deletion (Δ24) from the E1A gene to block the E1A‐Rb interaction, thus inhibiting Ad replication in normal cells.